SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine

Prabhat Pratap Singh Tomar, Isaiah T. Arkin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

82 Scopus citations

Abstract

COVID-19 is one of the most impactful pandemics in recorded history. As such, the identification of inhibitory drugs against its etiological agent, SARS-CoV-2, is of utmost importance, and in particular, repurposing may provide the fastest route to curb the disease. As the first step in this route, we sought to identify an attractive and viable target in the virus for pharmaceutical inhibition. Using three bacteria-based assays that were tested on known viroporins, we demonstrate that one of its essential components, the E protein, is a potential ion channel and, therefore, is an excellent drug target. Channel activity was demonstrated for E proteins in other coronaviruses, providing further emphasis on the importance of this functionally to the virus’ pathogenicity. The results of a screening effort involving a repurposing drug library of ion channel blockers yielded two compounds that inhibit the E protein: Gliclazide and Memantine. In conclusion, as a route to curb viral virulence and abate COVID-19, we point to the E protein of SARS-CoV-2 as an attractive drug target and identify off-label compounds that inhibit it.

Original languageAmerican English
Pages (from-to)10-14
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume530
Issue number1
DOIs
StatePublished - 10 Sep 2020

Bibliographical note

Publisher Copyright:
© 2020 Elsevier Inc.

Keywords

  • Anti-virals
  • Bacterial assays
  • COVID-19

Fingerprint

Dive into the research topics of 'SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine'. Together they form a unique fingerprint.

Cite this